Evidence map›Paper›PMID 27480849›Full record

ArticleAntimicrobial agents and chemotherapy2016

Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.

A Gonzalez-Serna, M Genebat, M De Luna-Romero, L Tarancon-Diez, B Dominguez-Molina, Y M Pacheco, M A Muñoz-Fernández, M Leal, E Ruiz-Mateos

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A Gonzalez-SernaMolecular Immunobiology Laboratory, General Universitary Hospital Gregorio Marañon, Health Research Institute Gregorio Marañon, Spanish HIV HGM BioBank, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain Laboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain alextantalo@hotmail.com ezequiel.ruizmateos@gmail.com.
M GenebatLaboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain.
M De Luna-RomeroLaboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain.
L Tarancon-DiezLaboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain.
B Dominguez-MolinaLaboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain.
Y M PachecoLaboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain.
M A Muñoz-FernándezMolecular Immunobiology Laboratory, General Universitary Hospital Gregorio Marañon, Health Research Institute Gregorio Marañon, Spanish HIV HGM BioBank, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain Viral and Immune Infection Unit Center, Institute of Health Carlos III, Majadahonda Campus, Molecular Immunobiology Laboratory, General Universitary Hospital Gregorio Marañon, Madrid, Spain.
M LealLaboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain.
E Ruiz-MateosLaboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain alextantalo@hotmail.com ezequiel.ruizmateos@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.

Indexed as

CyclohexanesHIVHIV Fusion InhibitorsHumansInhibitory Concentration 50MaravirocTriazolesViral TropismVirologyCyclohexanesHIV Fusion InhibitorsMaravirocTriazoles

Identifiers

PMID27480849
PMCPMC5038326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.